Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +15.00p +1.49% 1,022.50p 1,025.00p 1,028.00p 1,036.50p 987.60p 1,001.00p 696,398 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,579.1 170.1 53.9 21.3 2,460.94

Hikma Pharmaceuticals Share Discussion Threads

Showing 901 to 924 of 925 messages
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
12/1/2018
09:50
Full year result for 2017 to be announced on 14 March 2018. Trading update on 9th November 2017 was very positive. There is an issue beyond company's control is the devaluation of Egyptian pound. It was devalued in November from 8.8 to 17.6. So currently 17.6 Egyptian pounds buys you one USA dollar. This is good in one hand if your earning is in USA $, but makes goods produced in Egypt expensive ....I hope the company stops the share price drift south by updating the market befor 14th of March with some good news such as progress with PROGRESS with FDA submission.
karateboy
12/1/2018
08:54
If its any consolation, I was holding AAL when they dropped to £2.20 and were ranked as junk status. today they are sitting at £17.54. OK its a different sector, but you never know.
richrost
11/1/2018
19:06
What are your thoughts on the outlook for this to keep? I bought back then it was 16 so was thinking if I should cut losses or wait out for better times? Is it worth to wait at all? Thanks
bobogyo
10/1/2018
08:59
No worries then. Just flapping their lips to feel the breeze.
bantam175
10/1/2018
08:43
Jeffries downgrades to underperform : 894
soniraman
02/1/2018
15:34
Would buy This if it gets below 11as people have said strong balance sheet should make a profit reasonly good cash flow
mrthomas
19/12/2017
20:28
Hikma reaches licensing agreement with Celltrion for third biosimilar product in the Middle East and North Africa London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that it has reached a licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc (Celltrion) for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima(TM) (rituximab). Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima(TM) (rituximab), Remsima(R) (infliximab) and Herzuma(R) (trastuzumab) - in all its MENA markets. Truxima(TM) is mAb biosimilar to Roche's MabThera(R) (rituximab), which is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Truxima(TM) (rituximab) in all of its MENA markets, leveraging Hikma's strong local presence, biosimilar expertise, sales and marketing capabilities and regulatory expertise. Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, "We are pleased to be adding Truxima(TM) to our biosimilar and oncology portfolio, building on the success of our partnership with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients' access to high-quality, affordable medicines."
death by donut
19/12/2017
16:26
Do I detect a pulse? Suet
suetballs
15/12/2017
05:59
Treva cutting 25% of workforce? I wonder what Indian firms are doing? Industry shake out?
r ball
13/12/2017
12:45
Another new product announced today to boost earnings and profits
justiceforthemany
08/12/2017
16:27
Is this finally the start of the great fightback?
broadwood
05/12/2017
09:12
Was a mistake to buy this at £13.50. Low debt and healthy b/sheet so will hold for a while.
hickool
04/12/2017
19:37
H2 tends to be far stronger than H1. share price drop way overdone IMO as H1 2017 was no worse than H1 2016. After another drop today worst case this is trading on a P/E of just 12. Great balance sheet also.
justiceforthemany
20/11/2017
17:35
If fda settlement was sorted I would expect share price of £25. The main issue is Indian access to us generics market.
r ball
20/11/2017
14:31
Check the reports pye. When the share price dropped to 9 the forward P/E was 10.
justiceforthemany
20/11/2017
14:06
Well it took 9 months to get down here, how long to get back I wonder? Settlement with FDA on the cards maybe? Given current rise. Time will tell as always.
bantam175
19/11/2017
18:43
justice- stop posting incorrect data. This is not on a pe of 10.
pyemckay
16/11/2017
10:41
Gosh - could it be a blue day? Suet
suetballs
14/11/2017
15:29
Core earnings for this year are expected to be flat on 2016 at 118.5c/91p. A P/E of 10 is far too low for this sector and a company with a great balance sheet. Numis target of 1300p seems fair. Peel Hunt going for 1390p. Current share price of 950p is ridiculous and shorter driven. HIK Peel Hunt Hold 949.50 960.50 - *1,390.00 Target Price*
justiceforthemany
14/11/2017
08:30
got some at 913.2p. had quote for lower but didn't take it then couldn't buy for a minute. always the same at the bottom.
citytrader66
13/11/2017
16:04
Keep waiting for this to trend sideways before considering a purchase, but it keeps falling. 900p not all that far away.
its the oxman
09/11/2017
20:55
Surprised to see that they still have a major disagreement with FDA. It will be great if they can resolve the issue in Q1 2018 .
karateboy
09/11/2017
14:05
Could have been a shorters last hurrah before the big boys pile back in. The FDA problems started this slide. If it gets sorted out the upside should be excellent. Time will tell as always....
bantam175
09/11/2017
09:24
awful stuff, I do not understand why institutions were buying so heavily recently - they are losing millions - they haven't got a clue. maybe a bounce in coming days?
chc15
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180118 02:08:28